

# MedChem 2005 - Targeting the Brain, Successes and Pitfalls

## Programme

**Friday November 25, 2005**

- 08:00**      **Registration**
- 08:50**      **Introduction**
- 09:00**      **Conversion of the mushroom toxin Muscimol into THIP (Gaboxadol), a novel type of hypnotic and non-opioid analgesic**  
Prof. Povl KROGSGAARD-LARSEN  
(THE DANISH UNIVERSITY OF PHARMACEUTICAL SCIENCES, Copenhagen, Denmark)
- 09:50**      **Identification and biological evaluation of high affinity TRPV1 (VR1) vanilloid receptor antagonists**  
Dr Nicholas CARRUTHERS  
(JOHNSON & JOHNSON R&D, San Diego, United States)
- 10:40**      **Coffee break & poster session**
- 11:10**      **High throughput surface activity profiling in the prediction of blood-brain-barrier permeation**  
Prof. Paavo KINNUNEN  
(UNIVERSITY OF HELSINKI, Helsinki, Finland)
- 11:30**      **Towards a molecular understanding of presynaptic function: emerging targets for drug action**  
Dr Thomas C. SUDHOF  
(HOWARD HUGHES MEDICAL INSTITUTE, DALLAS, TX, United States)
- 12:20**      **Sandwich lunch & poster session**
- 13:20**      **Medicinal chemistry of CB1 cannabinoid receptor antagonists**  
Dr Jos LANGE  
(ABBOTT HEALTHCARE, WEESP, The Netherlands)
- 14:30**      **Optimisation of brain penetration in drug discovery**  
Dr Peter EDDERSHAW  
(UCB SA, CAMBRIDGE, United Kingdom)
- 15:20**      **P-glycoprotein, the gatekeeper: influence on the tissue distribution of the 5-HT<sub>1A</sub> antagonist P-[<sup>18</sup>F]MPPF, an ex vivo study in rats**  
Dr Alain PLENEVAUX  
(LIEGE UNIVERSITY CYCLOTRON, Liege, Belgium)
- 15:40**      **Coffee break & poster session**
- 16:10**      **Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity.**  
Dr Ralph CLINCKERS  
(VUB, Jette - Brussel, Belgium)
- 16:30**      **Discovery of GABA-A  $\alpha$ 2/3 subtype selective agonists for the treatment of anxiety**  
Dr Michael RUSSELL  
(MERCK SHARP & DOHME, Harlow, United Kingdom)

# MedChem 2005 - Targeting the Brain, Successes and Pitfalls

## Programme

---

17:20      Closing remarks